Author:
Rees Jon,Martins de Almeida Rodrigo,Ali Mahmood,Covernton Patrick J.O.,Stoelzel Matthias,Leyland Kirsten M.,Irwin Lucy,Scrine Ludmila,Hansen Merete Kock,Chapple Christopher
Reference20 articles.
1. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014
2. Harding CK, Lapitan MC, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. Arnhem, The Netherlands: European Association of Urology; 2022. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-neurogenic-Female-LUTS-2022_2022-05-12-115954_kvpr.pdf.
3. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder;Cardozo;J Urol,2004
4. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial;Homma;BJU Int,2003
5. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis;Chapple;Eur Urol,2008